← All indications
Leukemia, Prolymphocytic
A chronic leukemia characterized by a large number of circulating prolymphocytes. It can arise spontaneously or as a consequence of transformation of CHRONIC LYMPHOCYTIC LEUKEMIA.
Subtype terms (2)
More specific conditions that are subtypes of Leukemia, Prolymphocytic in the MeSH hierarchy.
- Leukemia, Prolymphocytic, B-Cell
22 drugs (15 approved, 7 experimental)
- Leukemia, Prolymphocytic, T-Cell
35 drugs (22 approved, 13 experimental)
Drugs by status
Phase 3 trials (6)
Phase 2 trials (42)
- allopurinol
- methylprednisolone
- acalabrutinib
- auranofin
- autologous t cells
- bendamustine
- busulfan
- lenalidomide
- clofarabine
- dinaciclib
- gemcitabine
- tacrolimus
- naltrexone
- idelalisib
- Filgrastim
- allogeneic stem cells
- ofatumumab
- ibrutinib
- atorvastatin
- carmustine
- sunitinib
- sotrastaurin
- cyclophosphamide
- autologous lymphocytes
- alemtuzumab
- Anti-thymocyte Globulin (Rabbit)
- veltuzumab
- anti-cd19/20-car vector-transduced t cells
- autologous regulatory t cells
- autologous umbilical cord blood
- +12 more
Phase 1 trials (16)
Organizations
Organization Involved with Phase 3 Indications (2)
Organization Involved with Phase 2 Indications (30)
- AbbVie
- MorphoSys
- Celgene
- Millennium Pharmaceuticals
- Immunomedics
- Pharmacyclics
- Genzyme
- Sanofi
- Novartis
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
- National Heart, Lung, and Blood Institute (NHLBI)
- Anhui Medical University
- Case Western Reserve University
- German CLL Study Group
- Johns Hopkins University
- Ohio State University
- Oregon Health and Science University
- Stanford University
- University of Kansas
- University of South Florida
- University of Witten/Herdecke
- University of Cologne
- University of Minnesota
- Acerta Pharma
- Medical University of Vienna
- University of Texas at Houston
- The Leukemia and Lymphoma Society
- Kansas Bioscience Authority
- People's Liberation Army of China
- Hefei University
Organization Involved with Phase 1 Indications (21)
- Cambridge Antibody Technology
- Amgen
- AstraZeneca
- MedImmune
- Arno Therapeutics
- Ascentage Pharma Group Inc.
- Karyopharm Therapeutics Inc
- Mundipharma
- Tesaro
- University of Pennsylvania
- University of Pittsburgh
- AIDS Malignancy Consortium
- Harvard University
- Wake Forest University
- Columbia University
- University of California, San Diego
- City of Hope National Medical Center
- University of Colorado
- CLL Consortium
- Damon Runyon Cancer Research Foundation
- OHSU Knight Cancer Institute
Organization Involved with Other Experimental Indications (1)